Japanese Encephalitis News and Research

RSS

Japanese encephalitis (previously known as Japanese B encephalitis to distinguish it from von Economo's A encephalitis) is a disease caused by the mosquito-borne Japanese encephalitis virus. The Japanese encephalitis virus is a virus from the family Flaviviridae. Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms. One of the most important vectors of this disease is the mosquito ''Culex tritaeniorhynchus''. This disease is most prevalent in Southeast Asia and the Far East.

Scientists identify potential drug target that disrupts Zika and similar viruses

Scientists potentially have found a way to disrupt Zika and similar viruses from spreading in the body.

17 Jun 2016

T memory cells with naive phenotype can help boost immunity in older adults

Sixty-five is the age when many people retire, kick back and take it easy. And so it often is with the human immune system.

14 Jun 2016

Purdue University-led researchers determine structure of Zika virus

A team led by Purdue University researchers is the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.

1 Apr 2016

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Researchers discover new JE virus transmission route

Japanese Encephalitis (JE) virus causes serious inflammation of the brain in people and fertility problems in pigs. Mosquitoes were previously the only known transmission route. However, the virus can also be spread from pig to pig by direct contact, and this could enable it to circulate in pigs during the mosquito-free winter season.

24 Feb 2016

Vaccinations could have significant economic value

Vaccinations, long recognized as an excellent investment that saves lives and prevents illness, could have significant economic value that far exceeds their original cost, a new study from researchers at the Johns Hopkins Bloomberg School of Public Health has found.

9 Feb 2016

SLU researcher discovered world's first dengue vaccine

A vaccine to prevent dengue fever discovered by a Saint Louis University researcher in 1997 and now licensed worldwide by Sanofi Pasteur has been approved for use in Mexico. Dengvaxia is the world's first vaccine approved to prevent dengue fever, which is a virus spread by mosquitoes primarily in tropical and sub-tropical areas.

15 Dec 2015

ADI develops ELISA test kits for detection of Ebola viral protein antibodies

San Antonio, Texas-based Biotech Company Alpha Diagnostic Int'l has developed and released several convenient, rapid, and sensitive ELISA test kits for the detection of major Ebola viral protein antibodies (Glycoprotein, GP; Nucleoprotein, NP, and Viral Protein 40 or VP40).

23 Oct 2014

Columbia University professor recommends vaccination for people travelling abroad

Planning to travel outside the U.S. this holiday season? Check with your primary care provider or travel clinic when you book your flight.

16 Oct 2014

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries.

8 Sep 2014

New research may help scientists develop treatments or vaccines for Dengue fever

Two recent papers by a University of Colorado School of Medicine researcher and colleagues may help scientists develop treatments or vaccines for Dengue fever, West Nile virus, Yellow fever, Japanese encephalitis and other disease-causing flaviviruses.

18 Apr 2014

WHO prequalifies affordable vaccine to protect children against Japanese encephalitis

An affordable vaccine to protect children against deadly Japanese encephalitis has been prequalified by the World Health Organization, paving the way to reach millions more children across Asia at risk for the disease.

10 Oct 2013

WHO approves new Japanese encephalitis vaccine to protect children in developing countries

A newly accessible vaccine against Japanese encephalitis (JE) is going to make the protection of more children in developing countries easier. The vaccine, manufactured in China, only needs to be given in one dose, it can be used for infants, and it is less expensive than other Japanese encephalitis vaccines.

9 Oct 2013

Rising temperature induces key changes in dengue virus

Researchers have discovered that rising temperature induces key changes in the dengue virus when it enters its human host, and the findings represent a new approach for designing vaccines against the aggressive mosquito-borne pathogen.

12 Apr 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

New research focuses on rapid identification of disease outbreaks

EcoHealth Alliance, the nonprofit organization that focuses on local conservation and global health issues, announced new research focused on the rapid identification of disease outbreaks in the peer reviewed publication, Journal of the Royal Society Interface.

15 Feb 2013

Sanofi Pasteur’s IMOJEV vaccine against Japanese encephalitis is now available in Australia

Sanofi Pasteur, the vaccines division of Sanofi, announced today that IMOJEV vaccine against Japanese encephalitis (JE) is now available in Australia.

10 Dec 2012

BMJ examines emergence of China as 'major new player' in global vaccine production

"The Chinese drug industry is on the verge of getting the green light to manufacture the Japanese encephalitis vaccine for the developing world, an event that will signal the emergence of a major new player in global vaccines," BMJ reports.

20 Sep 2012

Wellcome Trust awards University of Maryland $4M to accelerate development of conjugate NTS vaccine

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has received a $4 million Strategic Translation Award from the prestigious Wellcome Trust to support a collaboration with Bharat Biotech for clinical development of a new conjugate vaccine to prevent the potentially lethal infectious disease caused by invasive non-typhoidal Salmonella.

18 Jun 2012

Sinovac first quarter sales increase 30.3% to $6.0M

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2012.

15 May 2012